Chronic Refractory Cough (CRC) Market Set to Experience Unprecedented Growth During the Forecast Period (2023-32) - Estimates DelveInsight | Merck, Kyorin Pharmaceuticals, NeRRe Therapeutics, Bellus Health, Shionogi, Axalbion, Aldeyra Therapeutics

The Chronic Refractory Cough market size in the seven major markets was USD 8,740.2 million in 2021, which is further expected to increase by 2032. As per DelveInsight, the Chronic Refractory Cough Market is anticipated to evolve immensely in the coming years owing to the expected approval of emerging therapies and the increasing diagnosed prevalent population of Chronic Refractory Cough in the 7MM.

DelveInsight's "Chronic Refractory Cough Market Insights, Epidemiology, and Market Forecast 2032" report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Chronic Refractory Cough Market Size and Share in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).

The market report covers emerging drugs, treatment practices, market share of individual Chronic Refractory Cough therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current Chronic Refractory Cough treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of opportunities and assess the underlying potential of the market.

Chronic Refractory Cough: An Overview
Chronic Refractory Cough (CRC) is defined as a cough lasting more than 8 weeks despite guidelines-based treatment and which may be treated by different medical specialties only. Patients with chronic cough experience impaired quality of life and interruption of activities of daily living. It can result in depression and can persist for many months or years, despite systematic investigation and treatment of known causes. The infection can also be referred to as chronic cough (CC), chronic idiopathic cough (CIC), unexplained chronic cough (UCC), and cough hypersensitivity syndrome (CHS).

Recurrent incidence of CC results in CRC. The symptoms and indications of CRC are similar to those of CC. One of the first and most important symptoms that may indicate respiratory involvement is a persistent or chronic cough. Wheezing, stridor, dyspnea, hoarseness or aphonia, and discomfort over the laryngotracheal cartilage are other additional pulmonary symptoms and signs. A dry, irritating cough that is localized to the laryngeal region is one of the main symptoms.

CC is more prevalent in women, and there are various complications associated with it which include negative psychological, social, and physical outcomes. It causes an interruption of daily activities, social embarrassment, and physical exhaustion secondary to frequent coughing episodes.

Chronic Refractory Cough Market Key Facts
• The launch of potential Chronic Refractory Cough therapies, MK-7264 (gefapixant), BLU-5937, S-600918 (sivopixant), AX-8, and Orvepitant Maleate is expected to increase the market size in the coming years, assisted by the increase in the diagnosed prevalent population of Chronic Refractory Cough.
• The United States accounts for the largest Chronic Refractory Cough market size, in comparison to the EU-5 (Germany, Italy, France, Spain, and the United Kingdom) and Japan.
• Among the EU5 countries, Germany had the highest Chronic Refractory Cough market size, with approximately USD 837.4 million in 2021. This is expected to further increase, with Germany estimated to capture the maximum market, followed by the UK in 2032.
• In 2021, the 12-month prevalent cases of Chronic Refractory Cough were estimated to be 30,600+,000+ cases in the 7MM.
• Among the 7MM, the United States accounted for nearly 42% of the 12-month prevalent cases of CC with 12,782,168 cases in 2021 which are expected to increase further by 2032.
• Assessments as per DelveInsight's analysts show that the total diagnosed prevalent cases of CRC in the 7MM were 12,250,084 cases in 2021. Among the 7MM, in 2021, the US accounted for nearly 41.7% of the total diagnosed prevalent cases of CRC. The prevalent population for CRC was derived from the prevalent patient pool of CC.

Discover How the Chronic Refractory Cough Market Will Grow by 2032:
https://www.delveinsight.com/report-store/chronic-refractory-cough-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Chronic Refractory Cough Market
The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted market size by analyzing the impact of current and emerging Chronic Refractory Cough therapies in the market. It also provides a detailed assessment of the Chronic Refractory Cough market drivers & barriers, unmet needs, and emerging technologies.

The report gives complete detail of the market trend for each marketed Chronic Refractory Cough drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action (MOA), competition with other therapies, brand value, their impact on the market and view of the key opinion leaders.

Chronic Refractory Cough Epidemiology
The epidemiology section covers detailed insights into the historical, and current Chronic Refractory Cough patient pool and forecasted epidemiology trends for every seven major countries (7MM) from 2019 to 2032.

The Report Covers the Chronic Refractory Cough Epidemiology Segmented as -
• 12-month prevalent cases of Chronic Refractory Cough in the 7MM [2019-2032]
• Total Diagnosed Prevalent Cases of Chronic Refractory Cough in the 7MM [2019-2032]
• Gender-specific Cases of Chronic Refractory Cough in the 7MM [2019-2032]
• Diagnosed Prevalent Cases of Chronic Refractory Cough in IPF in the 7MM [2019-2032]

Get Key Insights Into the Evolving Chronic Refractory Cough Epidemiology Trends @
https://www.delveinsight.com/report-store/chronic-refractory-cough-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Chronic Refractory Cough Drugs Uptake and Pipeline Development Activities
The drugs' uptake section focuses on the rate of uptake of the potential drugs recently launched in the Chronic Refractory Cough market or expected to be launched during the study period. The analysis covers the market share by Chronic Refractory Cough drugs, patient uptake by therapies, and sales of each drug.

The report's drugs uptake section helps in understanding the drugs with the most rapid uptake and the reasons behind the maximal use of new drugs. It allows the comparison of the drugs based on market share and size, which again will be helpful in investigating factors important in understanding the market dynamics and in making financial and regulatory decisions.

The report also covers the Chronic Refractory Cough Pipeline Development Activities and provides valuable insights about different therapeutic candidates in Phase II and Phase III stages and the key companies in the market involved in developing targeted therapeutics. It also analyses recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Explore More About Ongoing Pipeline Development Activities @
https://www.delveinsight.com/sample-request/chronic-refractory-cough-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Chronic Refractory Cough Therapeutics Assessment
The current market for CRC is dominated by several non-effective treatment options such as neuro-modulating agents (opioids, baclofen, gabapentin, pregabalin, and amitriptyline), proton pump inhibitors, ICS, and others. Neuro-modulating agents occupy the major share of the current market. Moreover, the expected launch of emerging therapies, such as orvepitant maleate (Nerre Therapeutics), amlipixant (BLU-5937) (Bellus Health/GSK), MK-7264 (gefapixant) (Merck), AX-8 (Axalbion), and S-600918 (Shionogi), etc. shall also further create a positive impact on the Chronic Refractory Cough therapeutics market outlook and treatment scenario.

Leading Companies in the Chronic Refractory Cough Therapeutics Market Include
• Merck & Co
• Kyorin Pharmaceuticals
• NeRRe Therapeutics
• Bellus Health
• Shionogi
• Axalbion
• Aldeyra Therapeutics
And Many More

Emerging and Marketed Chronic Refractory Cough Therapies Covered in the Report Include
• MK-7264 (gefapixant): Merck & Co/ Kyorin Pharmaceuticals
• BLU-5937: Bellus Health
• S-600918 (sivopixant): Shionogi
• AX-8: Axalbion
And Many Others

Learn More About the Emerging Therapies & Key Companies in the Chronic Refractory Cough Therapeutics Market:
https://www.delveinsight.com/sample-request/chronic-refractory-cough-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Table of Content (TOC)
1. Key Insights
2. Executive Summary
3. Chronic Refractory Cough Competitive Intelligence Analysis
4. Chronic Refractory Cough Market Overview at a Glance
5. Chronic Refractory Cough Background and Overview
6. Chronic Refractory Cough Patient Journey
7. Chronic Refractory Cough Epidemiology and Patient Population
8. Chronic Refractory Cough Treatment Algorithm, Current Treatment, and Medical Practices
9. Chronic Refractory Cough Unmet Needs
10. Key Endpoints of Chronic Refractory Cough Treatment
11. Chronic Refractory Cough Marketed Products
12. Chronic Refractory Cough Emerging Therapies
13. Chronic Refractory Cough Seven Major Market Analysis
14. Attribute Analysis
15. Chronic Refractory Cough Market Outlook (7 major markets)
16. Chronic Refractory Cough Access and Reimbursement Overview
17. KOL Views on the Chronic Refractory Cough Market.
18. Chronic Refractory Cough Market Drivers
19. Chronic Refractory Cough Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
*The table of contents is not exhaustive; the final content may vary.

Download the Sample PDF to Get Detailed Insights About the Report's Offerings @
https://www.delveinsight.com/sample-request/chronic-refractory-cough-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

-------------------------------------------- xx --------------------------------------------
Other Trending Healthcare Reports by DelveInsight
Dementia with Diabetes Market
https://www.delveinsight.com/report-store/dementia-with-diabetes-market-forecast

Indolent Lymphoma Market
https://www.delveinsight.com/report-store/indolent-lymphoma-market

Liver Angiosarcoma Market
https://www.delveinsight.com/report-store/liver-angiosarcoma-market

Venous Stenosis Market
https://www.delveinsight.com/report-store/venous-stenosis-market

Bronchial Hyperreactivity Market
https://www.delveinsight.com/report-store/bronchial-hyperreactivity-market

Pegfilgrastim Biosimilar
https://www.delveinsight.com/report-store/pegfilgrastim-biosimilar-insight

Cytokine Release Syndrome Market
https://www.delveinsight.com/report-store/cytokine-release-syndrome-market

Primary Progressive Multiple Sclerosis (PPMS) Market
https://www.delveinsight.com/report-store/primary-progressive-multiple-sclerosis-ppms-market

Singapore Healthcare Outlook
https://www.delveinsight.com/report-store/singapore-healthcare-outlook-report

Hematuria Market
https://www.delveinsight.com/report-store/hematuria-market

Varicose Ulcer Market
https://www.delveinsight.com/report-store/varicose-ulcer-market

Anaplastic Astrocytoma Market
https://www.delveinsight.com/report-store/anaplastic-astrocytoma-market

Lymphoedema Market
https://www.delveinsight.com/report-store/lymphoedema-market

Morquio Syndrome Market
https://www.delveinsight.com/report-store/morquio-syndrome-market

Nasopharyngeal Carcinoma Market
https://www.delveinsight.com/report-store/nasopharyngeal-carcinoma-market

CART-related Neurotoxicity (NT) Market
https://www.delveinsight.com/report-store/cart-related-neurotoxicity-nt-market

Total Knee Arthroplasty Market
https://www.delveinsight.com/report-store/total-knee-arthroplasty-market

Cushing's Syndrome Market
https://www.delveinsight.com/report-store/cushings-syndrome-market

Tumor Ablation Market
https://www.delveinsight.com/report-store/tumor-ablation-market

Diabetes Market
https://www.delveinsight.com/report-store/diabetes-market

Autism Spectrum Disorder Market
https://www.delveinsight.com/report-store/autism-spectrum-disorder-asd-market

Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) Market
https://www.delveinsight.com/report-store/blastic-plasmacytoid-dendritic-cell-neoplasm-bpdcn-market

Urinary Incontinence Market
https://www.delveinsight.com/report-store/urinary-incontinence-market

Seborrhoeic Dermatitis Market Substance (Drug) Abuse Market
https://www.delveinsight.com/report-store/substance-drug-abuse-market

Artificial Cornea and Corneal Implant Market
https://www.delveinsight.com/report-store/artificial-cornea-and-corneal-implant-market

Prosthetic Heart Valve Market
https://www.delveinsight.com/report-store/prosthetic-heart-valve-market

Contact Info:
Shruti Thakur
Manager (Marketing & Branding)
Email: info@delveinsight.com

428, D21 Corporate Park, Sector-21, Dwarka, New Delhi-110077, India

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

This release was published on openPR.